« Return to News | CROs/Service Providers

Quintiles Acquires Targeted Molecular Diagnostics

Monday, December 1, 2008 09:15 AM

Global contract research organization (CRO) Quintiles has acquired Westmont, Ill.-based Targeted Molecular Diagnostics (TMD), a specialty diagnostic laboratory focused on oncology.

The addition of TMD’s services will strengthen Quintiles’ capabilities in oncology, a fast-growing area for drug development.

“This acquisition is a logical addition to Quintiles’ service offerings,” said Tom Wollman, Senior Vice President, Quintiles Global Central Laboratories, in a company release. “It provides us with advanced in-house pathology capabilities, including telepathology. Most importantly, TMD’s knowledge in biomarker expression analysis adds significant new proficiencies sought by our customers.”

Quintiles did not provide specifics about the deal, but TMD president, CEO and founder Sarah Bacus said she and her team are eager to join Quintiles’ team.

Founded in 2004, TMD supports clinical trials for pharmaceutical and biotech sponsors in over 40 countries. The company supports the development of numerous targeted therapies in oncology and offers over 100 biomarker assays.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.